Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

endpoint was based on an intent-to-treat (ITT) analysis, which included all patients randomized in the study. However, three patients did not receive study drug but were included in the analysis as nonresponders. In the primary analysis of the combined group of patients receiving either golimumab 50 mg or 100 mg in combination with MTX, 38 percent (40 percent receiving 50 mg and 37 percent receiving 100 mg) achieved at least 50 percent improvement in signs and symptoms of RA (ACR 50) through week 24, compared with 29 percent of patients receiving placebo plus MTX (p=0.053 for the combined group, p=0.042 for 50 mg and p=0.177 for 100 mg). When the three patients who did not receive golimumab were excluded in a modified intent-to-treat (mITT) analysis, the results showed that 39 percent of patients in the combined golimumab plus MTX group (41 percent receiving 50 mg and 37 percent receiving 100 mg) achieved ACR 50, compared with 29 percent of patients receiving placebo plus MTX (p=0.049 for the combined group, p=0.038 for 50 mg and p=0.177 for 100 mg). Additionally, 62 percent of patients in the combined golimumab plus MTX group (62 percent for each dose group) achieved ACR 20, compared with 49 percent receiving placebo plus MTX (p=0.011 for the combined group and p=0.028 for each dose group).

"These data show that treatment with golimumab induces an important depth of response, improving multiple aspects of rheumatoid arthritis and leading to significant decreases in disease activity," said Roy Fleischmann, M.D., Clinical Professor, Department of Internal Medicine at the University of Texas Southwestern Medical Center; Chief, Division of Rheumatology at St. Paul University Hospital in Dallas, Texas and lead study investigator. "Golimumab, which is an anti-TNF therapy, is a promising treatment option for multiple patient populations with this chronic and potentially debilitating inflammatory disease."

Also at week 24, patients receiving golimumab plus MT
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Inc., a leader in hand hygiene monitoring, today announced ... subsidiary of Ascendis Health Limited, in Johannesburg, ... of millions of patients around the world are affected ... patient to patient via the unwashed hands of healthcare ...
(Date:1/23/2015)... 23, 2015   Leatt Corporation  (OTCQB: LEAT), a global ... all forms of sports, including extreme motor sports, and ... today that the UISP Lega Motociclismo Lombardia, an Italian ... to wear a neck brace during its racing competitions.  ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... The two most,prevalent forms of genetic mental retardation, ... cause, according to researchers at,Stanford University School of ... brain, may also be associated with,autism., Although the ... result for the brain seems to be the ...
... YORK--(BUSINESS WIRE)--Apr 12, 2007 - INNOVIVE Pharmaceuticals,Inc. ... of INNO-406, a potent oral dual Bcr-Abl ... leukemia, will be presented at the American ... takes place April,14-18, 2007 at the Los ...
Cached Medicine Technology:Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 2Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 4Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting 2
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... DaVita,s Efforts in Corporate Social Responsibility and Support ... Calif., May 22 DaVita Inc. (NYSE: ... care services for those diagnosed with chronic kidney ... and marketing departments received eight Hermes Creative Awards, ...
... breast cancer had additional malignant tumors found only by ... Medical Center. , A total of 199 patients ... found additional, unsuspected cancers in the ipsilateral breast (the ... 16% of patients; we found cancers in the contralateral ...
... issued the,following press release: , ... flurry of panic about,the H1N1 (swine influenza). School ... even suggested closing the border with Mexico,where approximately three ... every day. The panic certainly was fueled by ...
... CyberKnife Centers Are Meeting Increasing Demand for ... TechnologiesSUNNYVALE, Calif., May 22 Accuray Incorporated ... leader in the field of radiosurgery, announced ... patient throughput using their recently installed, next ...
... Effort Addressing the Leading Cause of Maternal Mortality to ... Every year, more than half a million of the ... crisis that has seen little to no improvement over ... by Pathfinder International capitalized on groundbreaking new technologies in ...
... Reach $500 Million by 2014PRINCETON, N.J., May 22 ... federal funds next year and more than $500 million ... rules proposed to take effect in October, according to ... Economics department examined the impact of three provisions under ...
Cached Medicine News:Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 2Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 3Health News:H1N1: What You Should Know 2Health News:H1N1: What You Should Know 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 2Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 4Health News:New Initiative Poised To Reduce Maternal Mortality Rates By More Than 25 Percent 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 3
BD Vacutainer® Fluoride Tubes - Plastic...
Inquire...
Inquire...
... The inner wall of the serum ... particles, these particles activate the coagulation process. ... gel in the base of the tube; ... barrier between the serum and the blood ...
Medicine Products: